We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod ....

29 May 2025
KDST + NLSP Combined Core Investment Case 29052025
CRISPR Therapeutics AG (CRSP:NYSE), 0 | CRISPR Therapeutics AG (CRSP:NAS), 0 | DEXCOM (DXCM:NYSE), 0 | DexCom, Inc. (DXCM:NAS), 0 | Eli Lilly and Co (LLY:NYSE), 0 | Eli Lilly and Company (LLY:NYS), 0 | Hims & Hers Health, Inc. Class A (HIMS:NYS), 0 | INSULET (PODD:NYSE), 0 | Insulet Corporation (PODD:NAS), 0 | Kadimastem Ltd. (KDST:TAE), 0 | Medtronic plc. Ordinary Shares (MDT:NYSE), 0 | Medtronic Plc (MDT:NYS), 0 | NLS Pharmaceutics Ltd. (NLSP:NAS), 0 | Oramed Pharmaceuticals Incorporated (ORMP:TAE), 0 | Sana Biotechnology, Inc. (SANA:NAS), 0 | Sanofi (SAN:EPA), 0 | Sanofi SA (SAN:PAR), 0 | Senseonics Holdings Inc (SENS:NYSE), 0 | Senseonics Holdings, Inc. (SENS:ASE), 0 | Tandem Diabetes Care Inc (TNDM:NYSE), 0 | Tandem Diabetes Care, Inc. (TNDM:NAS), 0 | Teladoc (TDOC:NYSE), 0 | Teladoc Health, Inc. (TDOC:NYS), 0 | Tiziana Life Sciences Ltd. (TLSA:NAS), 0 | VERTEX PHARMACEUTICALS (VRTX:NYSE), 0 | Vertex Pharmaceuticals Incorporated (VRTX:NAS), 0

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
KDST + NLSP Combined Core Investment Case 29052025
CRISPR Therapeutics AG (CRSP:NYSE), 0 | CRISPR Therapeutics AG (CRSP:NAS), 0 | DEXCOM (DXCM:NYSE), 0 | DexCom, Inc. (DXCM:NAS), 0 | Eli Lilly and Co (LLY:NYSE), 0 | Eli Lilly and Company (LLY:NYS), 0 | Hims & Hers Health, Inc. Class A (HIMS:NYS), 0 | INSULET (PODD:NYSE), 0 | Insulet Corporation (PODD:NAS), 0 | Kadimastem Ltd. (KDST:TAE), 0 | Medtronic plc. Ordinary Shares (MDT:NYSE), 0 | Medtronic Plc (MDT:NYS), 0 | NLS Pharmaceutics Ltd. (NLSP:NAS), 0 | Oramed Pharmaceuticals Incorporated (ORMP:TAE), 0 | Sana Biotechnology, Inc. (SANA:NAS), 0 | Sanofi (SAN:EPA), 0 | Sanofi SA (SAN:PAR), 0 | Senseonics Holdings Inc (SENS:NYSE), 0 | Senseonics Holdings, Inc. (SENS:ASE), 0 | Tandem Diabetes Care Inc (TNDM:NYSE), 0 | Tandem Diabetes Care, Inc. (TNDM:NAS), 0 | Teladoc (TDOC:NYSE), 0 | Teladoc Health, Inc. (TDOC:NYS), 0 | Tiziana Life Sciences Ltd. (TLSA:NAS), 0 | VERTEX PHARMACEUTICALS (VRTX:NYSE), 0 | Vertex Pharmaceuticals Incorporated (VRTX:NAS), 0
- Published:
29 May 2025 -
Author:
Research Team ACF -
Pages:
15 -
We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod ....